Compare McKesson Corporation (MCK) vs Global X NASDAQ 100 Covered Call ETF (QYLD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
McKesson Corporation vs Global X NASDAQ 100 Covered Call ETF — how do they compare? McKesson Corporation trades at $878 (market cap $105.14B), while Global X NASDAQ 100 Covered Call ETF trades at $18.16. The key difference: McKesson Corporation pays a 0.42% dividend while Global X NASDAQ 100 Covered Call ETF pays none, and Global X NASDAQ 100 Covered Call ETF is trading nearer its 52-week high, McKesson Corporation nearer its low. Which is the better fit depends on your goals.
| MCK | QYLD | |
|---|---|---|
Market Cap | $105.14B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $995.69 | $18.52 |
52-Week Low | $659.01 | $16.46 |
Enterprise Value | $111.67B | — |
Dividend Yield | 0.42% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
McKesson (MCK) trades at $877.87, down 0.23% on the day, with strong technical momentum indicated by bullish moving averages and ADX signals. The company reported robust Q1 2027 results with EPS of $9.93 beating estimates by 20% year-over-year, driven by specialty drug growth and oncology performance. Revenue reached $105.4 billion, up 8%, prompting management to raise full-year adjusted EPS guidance. Analyst consensus remains strongly bullish with 24 buy ratings and a $990.67 price target, representing 13% upside potential.
MCK presents a compelling investment case with consistent earnings beats, raised guidance, and strong operational cash flow of $6.9 billion projected for 2026. Key risks include margin pressure from the low 1.12% net income margin, high accounts payable of $55.33 billion, and negative shareholder equity of -$2.07 billion. The stock's valuation at 24.19 P/E appears reasonable given growth prospects, but investors should monitor debt levels and pharmaceutical pricing dynamics.
QYLD trades at $18.18, up 0.17% with a bullish technical signal from moving averages but bearish oscillators. The ETF maintains its covered call strategy, generating consistent monthly dividends, though financial ratios are unavailable. Recent news highlights both the appeal of its 11.67% yield and concerns about long-term underperformance versus the Nasdaq-100.
Outlook: High income potential in sideways markets, but capital appreciation is limited. Risks include erosion of NAV during bull markets and competition from lower-fee alternatives. Suitable for income-focused investors willing to sacrifice growth for yield.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About McKesson Corporation
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →About Global X NASDAQ 100 Covered Call ETF
QYLD is an ETF that follows a covered call strategy on the NASDAQ 100 Index. The fund holds a long position in the stocks of the NASDAQ 100 and simultaneously writes (sells) call options on the index. The primary goal is to generate monthly income from the option premiums. This strategy can reduce portfolio volatility and provide income, but it limits potential capital appreciation from a significant rise in the NASDAQ 100 Index.
Read more on QYLD →
